Dr. Liesbeth Ceelen, Biotech leader and CEO of BioLizard

In this episode, Dr. Liesbeth Ceelen, Biotech leader and CEO of BioLizard, takes us on her incredible journey from scientist to entrepreneur, sharing her passion for the vibrant start-up and scale-up environment. Her extensive experience spans operational, quality, project management, scientific leadership, sales, and business development across various biotech and healthcare companies. If you're considering a career in Biotech, particularly in BD and management, or  being a freelance consultant, this episode is a must-listen!  “Don’t stop learning” “Dare to jump, just do it (...) even if it is not always easy to find the right job” “Don’t have too many doubts about yourself” and “Don’t be afraid of failure” “A ‘no’ you have a ‘yes’ you can get” Connect with Dr. Ceelen Dr. Ceelen’s Linkedin: https://www.linkedin.com/in/liesbethceelen/ Time points: 00:39 Introducing Dr. Liesbeth Ceelen 01:57  Dr. Ceelen’s motivation to do a PhD and her PhD journey 03:41 How Dr. Ceelen decided her next steps after her PhD, which doors were opened 05:50 PhD transferable skills that helped Dr. Ceelen to succeed in her first job in Pharma industry  08:13 Dr. Ceelen transition from Pharma to the startup ecosystem 13:17 Moving from scientist to BD and strategy roles - advice on training and learn at the job 15h47 Journey as a freelancer consultant and as a CEO of BioLizard 19h35 BioLizard business concept 21h20 Day at work - “every day is different” 24h12 Impactful experiences as a CEO of BioLizard  25h28 “Roses and thorns” as a CEO  27h13 BD strategy in Biotech in practice 29h28 5-year-planner” or “go with the flow”? 30h47 Dr. Ceelen piece of career advice 33h32 Advice on extra training for someone with affinity with BD and consulting 35h53 How to choose the next career path 37h12 Are you interested in joining BioLizard? Listen to the skill set and expertise that BioLizard is looking for 40h45 Connect with Dr. Ceelen

There are no comments yet.

Please log in to write the first comment.